AzTrials
AzTrials

AlcoholismNCT02233738

Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services

A study testing Group Motivational Interviewing (GMI) in people with Alcoholism and Substance-related Disorders, run by VA Office of Research and Development at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Homeless Veterans with substance use disorders (SUDs) are a major group served by VA and are heavily represented in VA housing. VA recently adopted a 'Housing First' approach emphasizing rapid housing placement to initiate recovery without requiring sobriety and will necessitate SUD interventions that are efficient… Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Group Motivational Interviewing (GMI)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
185 participants
Where
1 siteUnited States
Study dates
30 Sep 2015to 17 Jul 2018
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men and women Veterans currently in Housing Urban Development-VA Support Housing [HUD-VASH] and Grant and per Diem [GPD]), newly entering the program but not yet housed, or Veterans on the HUD-VASH interest (wait) list.
  • Able to comprehend English.
  • Meets DSM-V criteria for a current substance use disorder and have used substances in the 30 days prior to treatment entry. Participants on medications targeting their substance use must be stabilized on medications for at least 2 weeks before therapy initiation.
  • May meet criteria a mood, anxiety or other psychiatric disorder. Participants on maintenance medications for a mood or anxiety disorder must be stabilized on medications for at least 2 weeks before therapy initiation.
  • Able to adequately provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
  • Willing to commit to 4 group therapy sessions, baseline, 1, 3, and 6 month follow-up assessments.

Who cannot join

  • Active suicidal or homicidal ideation with a plan as this is likely to require hospitalization or other interventions that could interfere with study participation.
  • Unstable psychiatric condition that is likely to require hospitalization or other interventions that would interfere with study participation.
  • Unstable medical condition or one that may require hospitalization during the course of the study.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Ralph H. Johnson VA Medical Center, Charleston, SC

    Charleston, South Carolina, 29401-5703

Other trials in United States

About this study

Homeless Veterans with substance use disorders (SUDs) are a major group served by VA and are heavily represented in VA housing. VA recently adopted a 'Housing First' approach emphasizing rapid housing placement to initiate recovery without requiring sobriety and will necessitate SUD interventions that are efficient and easily layered onto existing services. The proposed study will investigate the effectiveness, implementation process, and cost estimate of Group Motivational Interviewing (GMI) for Veterans with SUDs in VA housing (Housing Urban Development-VA Support Housing [HUD-VASH] and Grant and per Diem [GPD]). Outcomes will be assessed at multiple time points using a multi-modal approach. The ultimate goal of this research is to establish the basis of a GMI dissemination and implementation course of action for highly vulnerable homeless Veterans in VA housing for achieving their greatest success in attaining housing stability.

Read the detailed description

Anticipated Impacts on Veterans Health Care:

VA set an ambitious goal for ending homelessness among Veterans by 2015. Housing Urban Development-VA Support Housing [HUD-VASH] and Grant and per Diem [GPD] are two primary VA housing programs to help Veterans exit homelessness. Substance abuse among Veterans in VA housing is a major risk factor for worsening psychopathology and housing instability. Despite recent adoption of a Housing First approach, many VA housing programs lack the staff infrastructure to manage substance use disorders (SUDs). This is a significant problem as 60% (conservative estimate) of Veterans in VA housing have SUDs and these Veterans show greater psychopathology compared to their counterparts without SUDs. These issues warrant substantial need for SUD programs in VA housing that are efficient to deploy, easily layered onto existing services, and require minimal staff to operate. The current study addresses this current void in VA treatment services in that it investigates the effectiveness, implementation process, and cost estimate of treatment of an adaptation of motivational interviewing, an empirically supported intervention with strong impact on reducing substance use and enhancing treatment engagement, in a group format, referred to as Group Motivational Interviewing (GMI) for Veterans with SUDs in VA housing. Data from this project, if shown to be promising, will establish the basis of a GMI dissemination and implementation course of action for highly vulnerable homeless Veterans in VA housing for achieving their greatest success in attaining housing stability.

Background:

There is a significant need for 'wraparound' treatment services in VA housing for addressing SUDs. Homeless Veterans with SUDs are vulnerable to treatment dropout, rendering them susceptible to relapse, while their continuation in outpatient care during their participation in VA housing leads to improved clinical outcomes. According to systematic reviews, individual motivational interviewing reduces the incidence of substance use disorders, when compared to no treatment, but is labor intensive. As VA moves toward a 'Housing First' paradigm where greater numbers of homeless Veterans will continue to use substances while in VA housing, delivery of GMI (which may be less labor intensive) to these patients will be important for initiating and maintaining their recovery as well as enhancing their psychosocial integration and quality of life. In a prior controlled trial conducted by the Principal Investigator, GMI resulted in significantly higher outpatient treatment engagement and lower substance use compared to treatment-as-usual among dually diagnosed Veterans.

Objectives:

Study objectives are consistent with VA housing recommendations focusing on patient recovery, health services promotion, and treatment implementation evaluation. GMI will be compared to a control treatment condition (CT) on (Specific Aim I; Five outcomes: (Primary Hypothesis 1): treatment engagement; (Primary Hypothesis 1): substance use; (Secondary H2): psychosocial integration (e.g., social support, community participation); (Secondary H3) quality of life/psychiatric indices; and (Secondary H4): number of days engaging in structured/productive work activities in the 6-month follow up. Specific Aim II involves a process evaluation for documenting (A) formative (e.g., developmental), (B) process, and (C) summative outcomes; and Specific Aim III involves estimation of cost of intervention in terms of direct costs, indirect costs of staff, costs of capital and workload measures for future implementation and dissemination research.

Methods:

Randomized controlled trial comparing GMI to control treatment (CT) across five critical outcomes. 186 Veterans in VA housing services (93 per treatment arm) will be enrolled with a diagnosis of alcohol or drug abuse/dependence. Recruitment will take place in Charleston VA Medical Center HUD-VASH \& GPD. Participants will be randomly assigned to (1) GMI or (2) CT, each consisting of 4 sessions, and will be evaluated at 1, 3, and 6 months. Participants with a non-substance related DSM-V disorder (e.g., major depressive disorder, PTSD) will be eligible for the study. Analyses will be conducted using generalized linear mixed models (GLMM) approach.

Significance to Veterans:

Homeless Veterans with SUDs represent one of the largest and most chronic groups of psychiatric patients treated in the VA Healthcare System. With the ongoing execution of VA's "Plan to End Veteran Homelessness," Veterans entering housing require interventions that can be feasibly implemented with minimal reorganization of existing services. GMI is based on motivational interviewing, an empirically valid treatment that aligns with Veteran-centered recovery models including Harm Reduction and more traditional treatment philosophies. The investment in GMI for VA housing may be minimal as it requires only a few staff to operate in relatively short time (e.g., 4 sessions, 90-min each) with modest (20 hours) staff training. It can be layered onto existing services with little interruption or reorganization of staff, and it has potential to be offered to larger numbers of Veterans with SUDs in VA housing who would otherwise not receive this intervention.

Being tested
Group Motivational Interviewing (GMI), Control Treatment Condition (CT)
Keywords
Alcoholism, Substance-related disorders, Dual Diagnosis
Medical subject headings
Alcoholism, Substance-Related Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Group Motivational Interviewing (GMI)Behavioural

    Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.

  • Control Treatment Condition (CT)Behavioural

    Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., "How do I talk to my family about my alcohol problem?"), money management with feedback (2 sessions), and cooking-home maintenance.

Study groups in NCT02233738
Study groupRoleWhat they receive
Group Motivational Interviewing (GMI)ExperimentalGroup Motivational Interviewing (GMI) participants will receive four structured, back-to-back, 90-min sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
Receives: Behavioral: Group Motivational Interviewing (GMI)
Control Treatment Condition (CT)Active comparatorControl Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to Group Motivational Interviewing (GMI) (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., "How do I talk to my family about my alcohol problem?"), money management with feedback (2 sessions), and cooking-home maintenance.
Receives: Behavioral: Control Treatment Condition (CT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Standard Ethanol Content Units (SECs) Baseline

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to baseline. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents ALL standard drinks consumed within the stated time period.

    Measured: 30 days prior to Baseline

  2. Standard Ethanol Content Units (SECs) at 1 Month

    The 1-month follow-up was conducted 30 days after day 1 of the treatment group. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to 1-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents ALL standard drinks consumed within the stated time period.

    Measured: 1 month

  3. Standard Ethanol Content Units (SECs) at 3 Months

    The 3-month follow-up was conducted 60 days after the 1-month follow-up. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents ALL standard drinks consumed within the stated time period.

    Measured: 3 months

  4. Standard Ethanol Content Units (SECs) at 6 Months

    The 6-month follow-up was conducted 90 days after the 3-month follow-up. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents ALL standard drinks consumed within the stated time period.

    Measured: 6 months

  5. Peak SEC at Baseline

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to baseline. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents the most standard drinks consumed in a single day within the stated time period.

    Measured: 30 days prior to Baseline

  6. Peak SEC at 1 Month

    The 1-month follow-up was conducted 30 days after day 1 of the treatment group. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to 1-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents the most standard drinks consumed on a single day within the stated time period.

    Measured: 1 month

  7. Peak SEC at 3 Months

    The 3-month follow-up was conducted 60 days after the 1-month follow-up. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents the most standard drinks consumed on a single day within the stated time period.

    Measured: 3 months

  8. Peak SEC at 6 Months

    The 6-month follow-up was conducted 90 days after the 3-month follow-up. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents the most standard drinks consumed on a single day within the stated time period.

    Measured: 6 months

  9. Alcohol Drink Days at Baseline

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to Baseline. This measure represents the number of days any alcohol was consumed within the stated time period.

    Measured: 30 days prior to Baseline

  10. Alcohol Drink Days at 1 Month

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days after day 1 of the treatment group. This measure represents the number of days any alcohol was consumed within the stated time period.

    Measured: 1 month

  11. Alcohol Drink Days at 3 Months

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. This measure represents the number of days any alcohol was consumed within the stated time period.

    Measured: 3 months

  12. Alcohol Drink Days at 6 Months

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. This measure represents the number of days any alcohol was consumed within the stated time period.

    Measured: 6 months

  13. Binge Drink Days at Baseline

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to Baseline. This measure represents the number of days the participant binge drank (5 or more standard drinks on a single day for males; 4 or more standard drinks on a single day for females).

    Measured: 30 days prior to Baseline

  14. Binge Drink Days at 1 Month

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to 1-month follow-up. This measure represents the number of days the participant binge drank (5 or more standard drinks on a single day for males; 4 or more standard drinks on a single day for females) within the stated time period.

    Measured: 1 month

  15. Binge Drink Days at 3 Months

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. This measure represents the number of days the participant binge drank (5 or more standard drinks on a single day for males; 4 or more standard drinks on a single day for females) within the stated time period.

    Measured: 3 months

  16. Binge Drink Days at 6 Months

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. This measure represents the number of days the participant binge drank (5 or more standard drinks on a single day for males; 4 or more standard drinks on a single day for females) within the stated time period.

    Measured: 6 months

  17. Illicit Drug Use Days at Baseline

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of drug use in the 30 days prior to Baseline. This measure represents the number of illicit drug use days within the stated time period.

    Measured: 30 days prior to Baseline

  18. Illicit Drug Use Days at 1 Month

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to 1-month follow-up. This measure represents the number of illicit drug use days within the stated time period.

    Measured: 1 month

  19. Illicit Drug Use Days at 3 Months

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. This measure represents the number of illicit drug use days within the stated time period.

    Measured: 3 months

  20. Illicit Drug Use Days at 6 Months

    The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. This measure represents the number of illicit drug use days within the stated time period.

    Measured: 6 months

  21. Substance Use Disorder Treatment Sessions at Baseline

    A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 30 days prior to Baseline. Treatment sessions included the outpatient substance use disorder treatment group sessions and individual sessions.

    Measured: 30 days prior to Baseline

  22. Substance Use Disorder Treatment Sessions at 1 Month

    A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 30 days prior to 1-month follow-up. Treatment sessions included the outpatient substance use disorder treatment group sessions and individual sessions.

    Measured: 1 month

  23. Substance Use Disorder Treatment Sessions at 3 Months

    A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 60 days prior to 3-month follow-up. Treatment sessions included the outpatient substance use disorder treatment group sessions and individual sessions.

    Measured: 3 months

  24. Substance Use Disorder Treatment Sessions at 6 Months

    A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 60 days prior to 6-month follow-up. Treatment sessions included the outpatient substance use disorder treatment group sessions and individual sessions.

    Measured: 6 months

  25. Twelve-Step Sessions Attended at Baseline

    A Treatment Attendance Calendar was used to record the number of self-reported 12-step sessions attended 30 days prior to Baseline.

    Measured: 30 days prior to Baseline

  26. Twelve-Step Sessions Attended at 1 Month

    A Treatment Attendance Calendar was used to record the number of self-reported 12-step sessions attended 30 days prior to 1-month follow-up.

    Measured: 1 month

  27. Twelve-Step Sessions Attended at 3 Months

    A Treatment Attendance Calendar was used to record the number of self-reported 12-step sessions attended 60 days prior to 3-month follow-up.

    Measured: 3 months

  28. Twelve-Step Sessions Attended at 6 Months

    A Treatment Attendance Calendar was used to record the number of self-reported 12-step sessions attended in the 90 days prior to 6-month follow-up.

    Measured: 6 months

  29. Times Involved in Community Participation Activities at Baseline

    A calendar was used to record the number of times a participant participated in an activity in the community (e.g. museum, library, baseball game) in the 30 days prior to Baseline.

    Measured: 30 days prior to Baseline

  30. Times Involved in Community Participation Activities at 1 Month

    A calendar was used to record the number of times a participant participated in an activity in the community (e.g. museum, library, baseball game) in the 30 days prior to 1-month follow-up.

    Measured: 1 month

  31. Times Involved in Community Participation Activities at 3 Months

    A calendar was used to record the number of times a participant participated in an activity in the community (e.g. museum, library, baseball game) in the 60 days prior to 3-month follow-up.

    Measured: 3 months

  32. Times Involved in Community Participation Activities at 6 Months

    A calendar was used to record the number of times a participant participated in an activity in the community (e.g. museum, library, baseball game) in the 90 days prior to 6-month follow-up.

    Measured: 6 months

  33. Days Involved in Productive Work Activities at Baseline

    A calendar was used to record the number of times a participant participated in a productive work activity (e.g. volunteered or worked at a job) in the 30 days prior to Baseline.

    Measured: 30 days prior to Baseline

  34. Days Involved in Productive Work Activities at 1 Month

    A calendar was used to record the number of times a participant participated in a productive work activity (e.g. volunteered or worked at a job) in the 30 days prior to 1-month follow-up.

    Measured: 1 month

  35. Days Involved in Productive Work Activities at 3 Months

    A calendar was used to record the number of times a participant participated in a productive work activity (e.g. volunteered or worked at a job) in the 60 days prior to 3-month follow-up

    Measured: 3 months

  36. Days Involved in Productive Work Activities at 6 Months

    A calendar was used to record the number of times a participant participated in a productive work activity (e.g. volunteered or worked at a job) in the 90 days prior to 6-month follow-up.

    Measured: 6 months

Secondary outcomes (47)
  1. Mental Health Treatment Sessions at Baseline

    A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 30 days prior to Baseline. Treatment sessions included individual sessions with outpatient mental health staff.

    Measured: 30 days prior to Baseline

  2. Mental Health Treatment Sessions at 1 Month

    A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 30 days prior to 1-month follow-up. Treatment sessions included individual sessions with outpatient mental health staff.

    Measured: 1 Month

  3. Mental Health Treatment Sessions at 3 Months

    A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 60 days prior to 3-month follow-up. Treatment sessions included individual sessions with outpatient mental health staff.

    Measured: 3 Months

  4. Mental Health Treatment Sessions at 6 Months

    A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 90 days prior to 6-month follow-up. Treatment sessions included individual sessions with outpatient mental health staff.

    Measured: 6 Months

  5. Substance Use Disorder and Mental Health Treatment Sessions at Baseline

    This specific measure combined the number substance use disorder treatment sessions and mental health treatment sessions attended for the 30 days prior to Baseline.

    Measured: 30 days prior to Baseline

  6. Substance Use Disorder and Mental Health Treatment Sessions at 1 Month

    This specific measure combined the number substance use disorder treatment sessions and mental health treatment sessions attended for the 30 days prior to 1-month follow-up.

    Measured: 1 Month

  7. Substance Use Disorder and Mental Health Treatment Sessions at 3 Months

    This specific measure combined the number substance use disorder treatment sessions and mental health treatment sessions attended for the 60 days prior to 3-month follow-up.

    Measured: 3 Months

  8. Substance Use Disorder and Mental Health Treatment Sessions at 6 Months

    This specific measure combined the number substance use disorder treatment sessions and mental health treatment sessions attended for the 90 days prior to 6-month follow-up.

    Measured: 6 Months

  9. Addiction Severity Index-Lite (ASI-Lite) at Baseline for Alcohol Use

    The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity

    Measured: 30 days prior to Baseline

  10. Addiction Severity Index-Lite (ASI-Lite) at 1 Month for Alcohol Use

    The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity

    Measured: 1 month

  11. Addiction Severity Index-Lite (ASI-Lite) at 3 Months for Alcohol Use

    The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity

    Measured: 3 months

  12. Addiction Severity Index-Lite (ASI-Lite) at 6 Months for Alcohol Use

    The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity

    Measured: 6 months

  13. Addiction Severity Index-Lite (ASI-Lite) at Baseline for Psychiatric Status

    The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity

    Measured: 30 days prior to Baseline

  14. Addiction Severity Index-Lite (ASI-Lite) at 1 Month for Psychiatric Status

    The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity

    Measured: 30 days

  15. Addiction Severity Index-Lite (ASI-Lite) at 3 Month for Psychiatric Status

    The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity

    Measured: 3 months

  16. Addiction Severity Index-Lite (ASI-Lite) at 6 Months for Psychiatric Status

    The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity

    Measured: 6 months

  17. Short Inventory of Problems (SIP) at Baseline

    Min value:0 Max value: 45 Higher score indicates higher number of consequences from alcohol and drug use

    Measured: 30 days prior to Baseline

  18. Short Inventory of Problems at 1 Month

    Min value:0 Max value: 45 Higher score indicates higher number of consequences from alcohol and drug use

    Measured: 1 month

  19. Short Inventory of Problems at 3 Months

    Min value:0 Max value: 45 Higher score indicates higher number of consequences from alcohol and drug use

    Measured: 3 months

  20. Short Inventory of Problems at 6 Months

    Min value:0 Max value: 45 Higher score indicates higher number of consequences from alcohol and drug use

    Measured: 6 months

  21. Social Support Survey Total Score at Baseline

    Min value:19 Max value:95 Higher score indicates higher support

    Measured: 30 days prior to Baseline

  22. Social Support Survey Total Score at 1 Month

    Min value:19 Max value:95 Higher score indicates higher support

    Measured: 30 days prior to 1-month follow-up

  23. Social Support Survey Total Score at 3 Months

    Min value:19 Max value:95 Higher score indicates higher support

    Measured: 60 days prior to 3-month follow-up

  24. Social Support Survey Total Score at 6 Months

    Min value:19 Max value:95 Higher score indicates higher support

    Measured: 90 days prior to 6-month follow-up

  25. Quality of Life Survey (QOLS) at Baseline

    Min value:16 Max value:112 Higher score indicates higher quality of life

    Measured: 30 days prior to Baseline

  26. Quality of Life Survey (QOLS) at 1 Month

    Min value:16 Max value:112 Higher score indicates higher quality of life

    Measured: 1 month

  27. Quality of Life Survey (QOLS) at 3 Months

    Min value:16 Max value:112 Higher score indicates higher quality of life

    Measured: 3 months

  28. Quality of Life Survey (QOLS) at 6 Months

    Min value:16 Max value:112 Higher score indicates higher quality of life

    Measured: 6 months

  29. Brief Symptom Inventory (BSI-18) at Baseline

    Min value:0 Max value:72 Higher score indicates higher psychological distress

    Measured: 30 days prior to Baseline

  30. Brief Symptom Inventory(BSI-18) at 1 Month

    Min value:0 Max value:72 Higher score indicates higher psychological distress

    Measured: 1 month

  31. Brief Symptom Inventory (BSI-18) at 3 Months

    Min value:0 Max value:72 Higher score indicates higher psychological distress

    Measured: 3 months

  32. Brief Symptom Inventory (BSI-18) at 6 Months

    Min value:0 Max value:72 Higher score indicates higher psychological distress

    Measured: 6 months

  33. SF-12 Health Survey Physical Summary Score at Baseline

    Physical summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health

    Measured: 30 days prior to Baseline

  34. SF-12 Health Survey Physical Summary Score at 1 Month

    Physical summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health

    Measured: 1 month

  35. SF-12 Health Survey Physical Summary Score at 3 Months

    Physical summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health

    Measured: 3 months

  36. SF-12 Health Survey Physical Summary Score at 6 Months

    Physical summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health

    Measured: 6 months

  37. SF-12 Health Survey Mental Summary Score at Baseline

    Mental summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health

    Measured: 30 days prior to Baseline

  38. SF-12 Health Survey Mental Summary Score at 1 Month

    Mental summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health

    Measured: 1 month

  39. SF-12 Health Survey Mental Summary Score at 3 Months

    Mental summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health

    Measured: 3 months

  40. SF-12 Health Survey Mental Summary Score at 6 Months

    Mental summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health

    Measured: 6 months

  41. Treatment Motivation Questionnaire (TMQ) at Baseline

    The TMQ will be used to measure self-reported interest in attending treatment Scores within each subscale are averaged

    External:

    Min value:1 Max value:7 External:Higher score indicates higher external reasons for attending treatment (e.g.referred to treatment by legal system)

    Internal:

    Min value:1 Max value:7 Internal: Higher score indicates higher internal reasons for attending treatment (e.g. personal choice to attend treatment)

    Measured: 30 days prior to Baseline

  42. Treatment Motivation Questionnaire (TMQ) at 1-month

    The TMQ will be used to measure self-reported interest in attending treatment Scores within each subscale are averaged

    External:

    Min value:1 Max value:7 External:Higher score indicates higher external reasons for attending treatment (e.g.referred to treatment by legal system)

    Internal:

    Min value:1 Max value:7 Internal: Higher score indicates higher internal reasons for attending treatment (e.g. personal choice to attend treatment)

    Measured: 30 days prior to 1-month follow-up

  43. Treatment Motivation Questionnaire (TMQ) at 3-month

    The TMQ will be used to measure self-reported interest in attending treatment Scores within each subscale are averaged

    External:

    Min value:1 Max value:7 External:Higher score indicates higher external reasons for attending treatment (e.g.referred to treatment by legal system)

    Internal:

    Min value:1 Max value:7 Internal: Higher score indicates higher internal reasons for attending treatment (e.g. personal choice to attend treatment)

    Measured: 60 days prior to 3-month follow-up

  44. Treatment Motivation Questionnaire (TMQ) at 6-months

    The TMQ will be used to measure self-reported interest in attending treatment Scores within each subscale are averaged

    External:

    Min value:1 Max value:7 External:Higher score indicates higher external reasons for attending treatment (e.g.referred to treatment by legal system)

    Internal:

    Min value:1 Max value:7 Internal: Higher score indicates higher internal reasons for attending treatment (e.g. personal choice to attend treatment)

    Measured: 90 days prior to 6-month follow-up

  45. Fagerstrom Test for Nicotine Dependence at Baseline

    Min:0 Max:10 Higher score indicates higher level of nicotine dependence

    Measured: 30 days prior to Baseline

  46. Psychiatric Outpatient Satisfaction Scale - Total Score

    Min:13 Max:65 Higher score indicates better satisfaction

    Measured: 1 month

  47. Helping Alliance Questionnaire - Total Score

    Participant completed assessment on the final day of group and rated therapist based on their interactions over the 4 days.

    Min:19 Max:114 Higher score indicates stronger alliance with therapist

    Measured: Completed during session 4 of treatment group (i.e. the final treatment session)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Sep 2014 (estimated)
  2. Study start30 Sep 2015
  3. Primary completion17 Jul 2018
  4. Study completion17 Jul 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
185 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02233738
Sponsor's protocol ID
IIR 13-317
Status last verified
Jul 2023
First submitted
21 Aug 2014
Last updated
27 Jul 2023
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Jaconis M, Santa Ana EJ, Killeen TK, Badour CL, Back SE. Concurrent treatment of PTSD and alcohol use disorder via telehealth in a female Iraq veteran. Am J Addict. 2017 Mar;26(2):112-114. doi: 10.1111/ajad.12481. Epub 2017 Jan 24.

    PubMed 28118514
  • Gebregziabher M, Voronca D, Teklehaimanot A, Santa Ana EJ. Weibull mixture regression for marginal inference in zero-heavy continuous outcomes. Stat Methods Med Res. 2017 Jun;26(3):1476-1499. doi: 10.1177/0962280215583402. Epub 2015 Apr 22.

    PubMed 25902801
  • Shorey RC, Martino S, Lamb KE, LaRowe SD, Santa Ana EJ. Change talk and relatedness in group motivational interviewing: a pilot study. J Subst Abuse Treat. 2015 Apr;51:75-81. doi: 10.1016/j.jsat.2014.11.003. Epub 2014 Nov 20.

    PubMed 25488505
  • Santa Ana EJ, LaRowe SD, Armeson K, Lamb KE, Hartwell K. Impact of group motivational interviewing on enhancing treatment engagement for homeless Veterans with nicotine dependence and other substance use disorders: A pilot investigation. Am J Addict. 2016 Oct;25(7):533-41. doi: 10.1111/ajad.12426. Epub 2016 Sep 2.

    PubMed 27589072

Questions about this trial

What is this clinical trial studying?

A study testing Group Motivational Interviewing (GMI) in people with Alcoholism and Substance-related Disorders, run by VA Office of Research and Development at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Dec 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Standard Ethanol Content Units (SECs) Baseline (time frame: 30 days prior to Baseline). The study lists 36 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02233738, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in